UBS O'Connor’s Oric Pharmaceuticals ORIC Stock Holding History

UBS O'Connor’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-80,000	Closed	-$50K	–	615
2024 Q1	$50K	Buy	+80,000	New	+$950K	﹤0.01%	444

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

UBS O'Connor's ORIC Position: Q3 2025 in Review

UBS O'Connor sold out of Oric Pharmaceuticals (ORIC) in Q3 2025, closing a stake of 49,000 shares — an estimated $497K sold.

UBS O'Connor first reported a position in ORIC in Q2 2022 and held it in 12 quarters. The position peaked at $2.81M in Q2 2023. 152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

UBS O'Connor reported no remaining Oric Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 49,000 Oric Pharmaceuticals shares in Q3 2025, an estimated $497K.
UBS O'Connor first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 12 quarters.
UBS O'Connor's Oric Pharmaceuticals position peaked at $2.81M in Q2 2023.
152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.